Nasal Corona Vaccine: AIIMS To Conduct Phase 2,3 Clinical Trial Of Bharat Biotech's Jab

After Bharat Biotech's Corona vaccine, the clinical trial of the same company's nasal vaccine will now be conducted at AIIMS, Delhi. The principal investigator of the trial will be Dr Sanjay Rai.

New Delhi: The clinical trial of Bharat Biotech's nasal Coronavirus vaccine will be held at All India Institute of Medical Science (AIIMS) Hospital in Delhi. The approval for this clinical trial has been sent to the AIIMS Ethics Committee. The trial of this nasal vaccine is expected to commence in the next couple of weeks. Earlier, Bharat Biotech's Covaxin has also been tested at AIIMS.

After the Covid-19 vaccine of Bharat Biotech, the clinical trial of the nasal vaccine of the same company will now be conducted at AIIMS, Delhi. The principal investigator of the trial will be Dr Sanjay Rai. Before conducting the trial, approval has to be taken from the Ethics Committee of AIIMS Hospital, which is under process and is expected to be cleared in the next one to two weeks. Dr Sanjay Rai, Community Medicine, AIIMS, says the trial will begin when ethical approval is given, Regulatory formalities will be completed, after which the trial will begin.

Nasal vaccine may be more effective

Dr Sanjay Rai, principal investigator of Bharat Biotech's Covaxin trial at AIIMS, believes that this nasal vaccine can be more effective. He hopes that it can prove effective in preventing the infection. Dr Sanjay Rai said there won't be any injection It will be administered through the nasal route. There is a possibility that such a vaccine will also be effective in preventing infection as it will give mucosal immunity. The vaccine that is currently given is not as effective in preventing infection. It is effective in preventing severity or preventing death.

The second and third phase of this nasal vaccine will be conducted at AIIMS. The trial of the second phase of this vaccine will be done on about 300 people. The second dose will be given four weeks after the first dose. This will be followed by a double-blind trial in the third phase of trials, in which some clinical trial volunteers will be given nasal vaccine and some will be given placebo. The clinical trial of Bharat Biotech's Covaxin has also been conducted at AIIMS Hospital in Delhi for the second and third phases, booster doses and 2 to 18-year-olds.